Cemex S.A.B. de C.V. Sponsored ADR vs Nuwellis Inc — how do they compare? Cemex S.A.B. de C.V. Sponsored ADR trades at $9.56 (market cap $13.84B), while Nuwellis Inc trades at $0.69 (market cap $2.20M). The key difference: Cemex S.A.B. de C.V. Sponsored ADR is far larger — about 6290.9× Nuwellis Inc's market cap, and Cemex S.A.B. de C.V. Sponsored ADR pays a 1.3% dividend while Nuwellis Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cemex S.A.B. de C.V. Sponsored ADR for 0 Days and Nuwellis Inc for 26 Days on average.
| CX | NUWE | |
|---|---|---|
Market Cap | $13.84B | $2.20M |
Volume | 6,589,714 | 121,544 |
Sector | Basic Materials | Health |
52-Week High | $13.55 | $146.65 |
52-Week Low | $9.12 | $0.68 |
Typical Hold Time | 0 Days | 26 Days |
Enterprise Value | $19.83B | -$1.52M |
Dividend Yield | 1.3% | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
NUWE trades at $0.6907, down 1.48% on the day, with a bearish technical signal from moving averages despite oversold RSI readings. The company reported revenue growth to $9M in 2026 but remains deeply unprofitable with a net income margin of -125.63%. Recent news highlights console sales growth and strategic expansions in pediatric and critical care markets.
The outlook is high-risk due to persistent losses and negative cash flow, though analyst sentiment is split with a 50% buy rating. Investment potential hinges on the company's ability to achieve profitability and scale its Aquadex platform, while risks include cash burn and competitive pressures in the medical device sector.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Cemex produces, distributes, markets, and sells cement, ready-mix concrete, aggregates, and other construction materials. Its operations serve markets around the world.
Read more on CX →Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →